Are chemotherapy-free treatment strategies an option for patients with PH+ ALL?

During the 2022 ASCO Annual Meeting, the ALL Hub spoke with Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Are chemotherapy-free treatment strategies an option for patients with PH+ ALL?

Short begins by discussing historic treatments for patients with PH+ ALL, their survival, and relapse rates. Short highlights the value of lower-intensity therapies than chemotherapy, which might have fewer risks of complications, and outlines modern chemotherapy-free therapies, like blinatumomab, and their response rates and high rates of MRD negativity. Finally, Short discusses the D-ALBA study and the investigation into ponatinib and blinatumomab.